Not yet recruiting
Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial
NCT07910435· Phase 2· University of Washington· Source
Contact: Stephen D. Smith, MD
Not yet recruiting
Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT07887061· Phase 2· Fred Hutchinson Cancer Center· Source
Contact: Jennifer J. Huang, MD, PhD
Not yet recruiting
Remote Screening and Navigation to Increase Trial Enrollment, INVITE Trial
NCT07908407· Fred Hutchinson Cancer Center· Source
Contact: Hiba M. Khan, MD
Not yet recruiting
Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome
NCT07819396· Phase 2· Fred Hutchinson Cancer Center· Source
Contact: Phuong Vo, MD
Not yet recruiting
IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate Cancer
NCT07803653· Phase 1· Fred Hutchinson Cancer Center· Source
Contact: Fred Hutch Intake
Recruiting
FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia
NCT07645469· Phase 1· Fred Hutchinson Cancer Center· Source
Contact: Fred Hutch Immunotherapy Intake
Recruiting
An Educational Intervention (Lung Toolkit) for Improving Knowledge About Lung Cancer and Screening Among American Indian and Alaskan Native Cigarette Smokers, Lung PATHS Trial
NCT07615764· Fred Hutchinson Cancer Center· Source
Contact: Nicolas Anderson
Recruiting
Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer
NCT07645651· Phase 1· University of Washington· Source
Contact: Isabel Blanco
Recruiting
A Home-Based Exercise Intervention (CAREFit-BMT) in Improving Heart Function Among Patients With High Risk Acute Myeloid Leukemia Undergoing Stem Cell Transplant
NCT07616921· University of Washington· Source
Contact: Alexi Vasbinder, PhD, RN
Not yet recruiting
Neoadjuvant Intravesical Nadofaragene Firadenovec With Enfortumab Vedotin and Pembrolizumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial
NCT07332351· Phase 2· University of Washington· Source
Contact: Jonathan Wright, MD
Recruiting
Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial
NCT07466498· Phase 2· Fred Hutchinson Cancer Center· Source
Contact: Michael Schweizer, MD
Recruiting
Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT07194980· Phase 2· Fred Hutchinson Cancer Center· Source
Contact: Fred Hutch Immunotherapy Intake
Not yet recruiting
iCanQuit Smoking Cessation Among Hispanic Adults
NCT06811038· Phase 3· Fred Hutchinson Cancer Center· Source
Contact: Jonathan Bricker, PhD
Recruiting
A Restorative Justice-Based Lung Cancer Screening Decision-Making Support Intervention Tailored for Black Individuals to Increase Lung Cancer Screening Among Black Community Members, RESTORE Trial
NCT07490860· Fred Hutchinson Cancer Center· Source
Contact: Matthew Triplette, MD, MPH
Not yet recruiting
A Smartphone Application (QuitBot) for the Improvement of Smoking Cessation Among American Indians and Alaska Natives, NAITIVE Trial
NCT06697496· Fred Hutchinson Cancer Center· Source
Contact: Jonathan Bricker, PhD
Not yet recruiting
Testing Pasritamig Before Surgery for the Treatment of Localized Prostate Cancer
NCT07860255· Phase 1· Fred Hutchinson Cancer Center· Source
Contact: Fred Hutch Immunotherapy Intake
Recruiting
Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial
NCT07698535· Phase 2· University of Washington· Source
Contact: Michael Schweizer, MD
Not yet recruiting
A Behavioral Application for Improving Smoking Cessation Among Smokers
NCT07493252· Fred Hutchinson Cancer Center· Source
Contact: Jaimee Heffner, PhD
Not yet recruiting
A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden
NCT07721259· Phase 2· University of Washington· Source
Contact: Research Coordinator(s)
Recruiting
Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer
NCT07667335· Phase 1/2· Fred Hutchinson Cancer Center· Source
Contact: Rosa Nadal Rios, MD, PhD
Recruiting
Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms
NCT07094750· Fred Hutchinson Cancer Center· Source
Contact: Jacob Appelbaum, MD, PhD
Recruiting
Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma
NCT07731789· Phase 2· University of Washington· Source
Contact: Mengyang Di, MD, PhD
Recruiting
[18F]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine, Cisplatin, and Durvalumab for Newly Diagnosed Cholangiocarcinoma
NCT07673341· Phase 2· University of Washington· Source
Contact: Angela Castellanos Rodriguez, MD, MSc
Recruiting
SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
NCT07322341· Phase 2· University of Washington· Source
Contact: Rebecca Wood
Recruiting
IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence
NCT07495124· Phase 2· University of Washington· Source
Contact: CVI Coordinators
Recruiting
Uterine Lavage to Detect Ovarian Cancer Risk
NCT07772869· University of Washington· Source
Contact: Intake Coordinators
Recruiting
Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial
NCT07579195· Phase 1/2· University of Washington· Source
Contact: T. Martin Ma, MD, PhD
Recruiting
A Digital Intervention (ACT on Vaping App) for Vaping Cessation in Young Adult E-Cigarette Users
NCT06909500· Fred Hutchinson Cancer Center· Source
Contact: Jaimee Heffner, PhD
Recruiting
Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease
NCT07535008· Fred Hutchinson Cancer Center· Source
Contact: Armin Rashidi, MD, PhD
Recruiting
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
NCT07224100· Phase 2· University of Washington· Source
Contact: Ryan Cassaday, MD
Recruiting
A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
NCT07078604· Phase 2· University of Washington· Source
Contact: Research Coordinator(s)
Recruiting
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
NCT07181941· Phase 1/2· Fred Hutchinson Cancer Center· Source
Contact: Madhav Dhodapkar, MBBS
Recruiting
Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Among Patients With Non-muscle Invasive Bladder Cancer, The EMPOWER Trial
NCT07302230· University of Washington· Source
Contact: Sarah Psutka, MD, MSc
Recruiting
Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms
NCT07148947· Phase 2· University of Washington· Source
Contact: Anna Halpern, MD
Recruiting
[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer
NCT06502691· Phase 1/2· University of Washington· Source
Contact: Jennifer Specht, MD
Recruiting
Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians
NCT07282158· Fred Hutchinson Cancer Center· Source
Contact: Megan J. Shen, PhD
Recruiting
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
NCT07228624· Phase 2· Fred Hutchinson Cancer Center· Source
Contact: Rachel Salit, MD
Recruiting
Exercise Training for the Improvement of Immune Activity and Treatment Outcomes During Immunotherapy for Non-small Cell Lung Cancer, BOOST Trial
NCT06983899· Fred Hutchinson Cancer Center· Source
Contact: Dong-Woo Kang, PhD
Recruiting
Rifaximin Versus No Intervention for the Treatment of IgG/IgA (Non-IgM) Monoclonal Gammopathy of Undetermined Significance
NCT07209371· Phase 2· Fred Hutchinson Cancer Center· Source
Contact: Madhav Dhodapkar, MBBS
Recruiting
A Multilevel Intervention to Increase Colorectal Cancer Screening Tests in Patients With Abnormal Fecal Immunochemical Test Results, PROACT Trial
NCT06822530· Fred Hutchinson Cancer Center· Source
Contact: Rachel B. Issaka, MD, MAS
Recruiting
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
NCT07097363· Phase 2· University of Washington· Source
Contact: Mengyang Di, MD, PhD
Recruiting
Improving Uptake of Surveillance in Colorectal Cancer Survivors Through Navigation and Web Education
NCT06995924· Fred Hutchinson Cancer Center· Source
Contact: Ari Bell-Brown
Recruiting
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
NCT06948786· Phase 2· University of Washington· Source
Contact: Mengyang Di, MD, PhD
Recruiting
A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT07112053· Phase 2· University of Washington· Source
Contact: Research Coordinator(s)
Recruiting
Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
NCT07225127· University of Washington· Source
Contact: Sung Min Kim
Recruiting
Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
NCT06710418· University of Washington· Source
Contact: Anna Halpern, MD
Recruiting
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
NCT07046078· Phase 2· Fred Hutchinson Cancer Center· Source
Contact: Filippo Milano, MD, PhD
Active, not recruiting
Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia
NCT06752694· Phase 2· Fred Hutchinson Cancer Center· Source
Recruiting
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
NCT06928662· Phase 1/2· Fred Hutchinson Cancer Center· Source
Contact: Naveed Ali, MD
Recruiting
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
NCT06784726· Phase 2· University of Washington· Source
Contact: Mengyang Di, MD, PhD
Showing 50 of 113.